Sarah Bennett
Hepatitis B core antibodies (anti-HBc) are found in almost all individuals previously exposed to the hepatitis B virus (HBV). However, the presence of anti-HBc alone does not indicate the activity of the disease. The isolated hepatitis B core antibody serologic profile, defined as positive anti-HBc with negative HBsAg and anti-HBs, can be observed in patients with chronic hepatitis C. The hepatitis B vaccine has been shown to control the disease effectively, even in endemic areas, but its benefit for patients with isolated core antibodies is still uncertain.
| Characteristics | Values |
|---|---|
| Hepatitis B core antibodies | Detected in almost every patient with previous exposure to hepatitis B virus (HBV) |
| Hepatitis B surface antibodies | Produced in response to vaccination or HBV infection |
| Hepatitis B core antibody serologic profile | Positive anti-HBc with negative HBsAg and anti-HBs |
| Prevalence in patients with chronic hepatitis C | Relatively uncommon |
| Implications of true-positive isolated IgG anti-HBc | Transmission of HBV infection to others through blood or organ donation; HBV reactivation during chemotherapy or immune-modulating therapy |
| DNA vaccine cocktail | Expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques |
Explore related products
What You'll Learn
- Hepatitis B core antibodies (anti-HBc) are detected in almost all individuals previously exposed to the virus
- Vaccination campaigns have been shown to control the disease, even in endemic areas
- A positive hepatitis B core antibody result may indicate an active infection
- A single dose of HBV vaccine should prompt an anamnestic response
- The isolated hepatitis B core antibody serologic profile can be seen in 1-30% of patients
Hepatitis B core antibodies (anti-HBc) are detected in almost all individuals previously exposed to the virus
Hepatitis B core antibodies (anti-HBc) are considered the most sensitive and reliable markers of HBV exposure. They are detected in almost all individuals who have been previously exposed to the hepatitis B virus (HBV). However, it is important to note that anti-HBc alone cannot determine the activity of the disease.
The presence of anti-HBc indicates exposure to HBV, but it does not indicate vaccine failure unless the hepatitis B surface antigen (HBsAg) or HBV DNA becomes positive, signalling a productive HBV infection. Anti-HBc can be detected in individuals with acute or chronic HBV infection, and it is one of the three main serologic markers used to determine HBV infection status, along with HBsAg and antibody to HBsAg (anti-HBs).
During acute infection, anti-HBc IgM increases rapidly and is part of the first-line testing for patients with high ALT levels and liver dysfunction. Although anti-HBc IgM usually disappears after 6-12 months, it may reappear during a hepatitis flare in chronic infection. High anti-HBc IgM titers indicate an acute infection. In ongoing HBV infection, anti-HBc is detected alongside HBsAg.
The detection of anti-HBc is significant in understanding an individual's exposure to HBV and their immune response. It is important to distinguish between natural infection and vaccination, as the interpretation and management of anti-HBc may vary in these contexts. For example, the presence of anti-HBc in vaccinated individuals may indicate an anamnestic response due to prior infection and immunity, as seen in some patients in a study by Su et al. (2012).
In summary, hepatitis B core antibodies (anti-HBc) are highly indicative of previous exposure to the hepatitis B virus (HBV) and play a crucial role in clinical practice for HBV diagnosis and management.
Treating Baby Fever Post-Vaccination: A 2-Month Guide
You may want to see also
Explore related products
Vaccination campaigns have been shown to control the disease, even in endemic areas
Hepatitis B vaccination campaigns have been shown to control the disease effectively, even in areas where it is endemic. Hepatitis B core antibodies (anti-HBc) are found in almost all individuals previously exposed to the virus. However, the presence of these antibodies alone does not indicate the activity of the disease.
In Malaysia, for example, the inclusion of the hepatitis B vaccine in the national immunization program significantly reduced the rate of hepatitis B surface antigen (HBsAg) positivity from 5.5% to 0.3%. Clinical serological surveys conducted in other parts of the world, such as China, have shown that anti-HBs levels can wane over time, and isolated anti-HBc was found in 1% to 9% of vaccines after 10 to 15 years of primary vaccination.
In a study of vaccinated undergraduate students in Malaysia, 408 participants who received infant hepatitis B vaccinations provided blood samples for testing. The results showed that hepatitis B core antibodies were detected in those with previous exposure to the virus. However, the study aimed to investigate the implications of isolated hepatitis B core antibodies and evaluate the effect of hepatitis B vaccine boosters in this cohort.
Another study in Taiwan examined the response of isolated anti-HBc-positive subjects to the recombinant hepatitis B vaccine. The results indicated that hepatitis B vaccination, followed by anti-HBs measurement, could identify evidence of past infection and exclude chronic infection in a significant number of patients.
While there is currently no effective vaccine against hepatitis C, vaccination campaigns for hepatitis B have proven successful in controlling the disease, even in regions with high endemicity. These campaigns have contributed to a significant decrease in the prevalence of hepatitis B surface antigen and provided long-term protective immunity.
MMR Vaccines: Single Shots Licensed in the UK?
You may want to see also
Explore related products
A positive hepatitis B core antibody result may indicate an active infection
Hepatitis B core antibodies (anti-HBc) are found in almost all individuals who have been exposed to the hepatitis B virus (HBV). However, the presence of these antibodies alone does not indicate whether the infection is active or past. A positive hepatitis B core antibody test result indicates that a person has been exposed to the hepatitis B virus at some point in their life. This test detects the presence of antibodies produced by the body in response to the hepatitis B virus.
It's important to note that a positive hepatitis B core antibody result does not provide any protection against the hepatitis B virus. This is in contrast to the hepatitis B surface antibody (anti-HBs), which indicates that a person is immune and protected against the virus after recovering from a past infection or receiving the vaccine. Therefore, a positive hepatitis B core antibody result may indicate a current or past infection, but it does not provide immunity.
The interpretation of a positive hepatitis B core antibody result depends on the presence or absence of other markers, such as the hepatitis B surface antigen (HBsAg) and the hepatitis B e-antigen (HBeAg). If the hepatitis B core antibody is detected in isolation, without the presence of HBsAg or anti-HBs, it could indicate a "window period" during acute hepatitis B when HBsAg is no longer detectable, but anti-HBs has not yet developed. This can occur during the recovery phase of the infection.
In some cases, a positive hepatitis B core antibody result may indicate an active infection, especially if other markers suggest ongoing infection. For example, the presence of IgM anti-HBc, a specific type of hepatitis B core antibody, indicates a new acute hepatitis B infection. Additionally, the detection of HBeAg, which is associated with higher HBV DNA levels, suggests increased infectiousness and can be present in acute or chronic infections.
To fully understand the implications of a positive hepatitis B core antibody result, it is crucial to consult with a healthcare provider. They may recommend additional blood tests, such as those for HBsAg, anti-HBs, and HBeAg, to determine the status of the infection and rule out other types of hepatitis infections, as the symptoms of all five hepatitis infections are similar. Based on the comprehensive test results, a healthcare provider can provide an accurate interpretation and determine the appropriate course of action, which may include monitoring, treatment, or further evaluation by a liver specialist.
Mandatory Vaccinations for Home Health Aides: What's the Verdict?
You may want to see also
Explore related products
$11.69 $15.99
A single dose of HBV vaccine should prompt an anamnestic response
Hepatitis B is a liver disease caused by the hepatitis B virus (HBV). The hepatitis B vaccine is safe and effective and can provide a lifetime of protection against a preventable chronic liver disease. It is also known as the first "anti-cancer" vaccine as it prevents hepatitis B, the leading cause of liver cancer worldwide.
The hepatitis B vaccine is available at doctor's offices, local health departments, and clinics. The CDC recommends the hepatitis B vaccine for all newborns, children up to 18 years of age, adults 19-59 years of age, and adults 60 and older who are at high risk of infection. People aged 19 and younger should receive three doses, while people aged 20 and older should receive three doses as well. Adults on dialysis or predialysis should receive three doses of the dialysis formulation, while adults on hemodialysis should receive four doses. Babies born to infected mothers must receive the first dose of the hepatitis B vaccine in the delivery room or within the first 12 hours of life. The second shot should be administered at least one month after the first, and the third shot at least four months after the first and two months after the second.
A single dose of the HBV vaccine should prompt an anamnestic response. Studies indicate that immunologic memory remains intact for at least 30 years and confers protection against clinical illness and chronic HBV infection. If exposed to HBV, people with competent immune systems will mount an anamnestic response and develop protective anti-HBs.
Hepatitis B core antibodies (anti-HBc) are detected in almost every patient with previous exposure to the hepatitis B virus (HBV). However, this marker alone does not indicate the activity of the disease. A long-term response can be predicted by measuring anamnestic responses after the administration of a booster dose, HBV core antibody (anti-HBc), the prevalence of infection in the vaccinated cohort, and in vitro B and T cell activity testing.
Pharmacists Vaccinating: Legal in Florida?
You may want to see also
Explore related products
The isolated hepatitis B core antibody serologic profile can be seen in 1-30% of patients
The isolated hepatitis B core antibody serologic profile is defined as a positive anti-HBc with negative HBsAg and anti-HBs. This profile can be seen in 1-30% of patients with HIV coinfected with hepatitis C virus (HCV). The prevalence of this profile increases with age, ranging from 0.8% in individuals aged 21-30 to 2.4% in those aged 31-40.
The presence of isolated hepatitis B core antibodies (anti-HBc) suggests previous exposure to the hepatitis B virus (HBV). However, it does not provide information about the activity of the disease. Anti-HBc is the earliest antibody to develop in response to HBV infection and can persist for life. The detection of anti-HBc alone can indicate chronic infection, with undetectable HBsAg.
The interpretation of HBsAg and anti-HBs negativity, despite anti-HBc positivity, should be approached with caution. It may indicate acute infection, resolving or resolved acute infection, false-negative anti-HBs results, false-positive anti-HBc results, or low-level/false-negative HBsAg results in chronically infected patients.
The isolated anti-HBc profile has been observed in varying liver progression outcomes in HIV-infected cohorts. While one study suggested no association with accelerated liver progression, another found a link with more advanced hepatic fibrosis in patients with HIV/HCV coinfection.
The management of the isolated anti-HBc profile in the context of HBV prevention and HCV therapy is crucial due to the potential for HBV reactivation during HCV treatment. Vaccination responses in individuals with this profile can help elucidate the cause and guide therapeutic strategies.
Distemper and Parvo: Are These Vaccines Interchangeable?
You may want to see also
